138 related articles for article (PubMed ID: 36531081)
1. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
Cárdenas MC; Iñigo B; Ortega I; Palomar MA; Menéndez M; Plaza P; Martínez-Novillo M; Benavente C
Front Oncol; 2022; 12():1056293. PubMed ID: 36531081
[TBL] [Abstract][Full Text] [Related]
2. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.
Narita K; Miura D; Tsushima T; Terao T; Kuzume A; Tabata R; Takeuchi M; Matsue K
Sci Rep; 2021 Jul; 11(1):14956. PubMed ID: 34294772
[TBL] [Abstract][Full Text] [Related]
3. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma.
Natsuhara KH; Huang CY; Knoche J; Arora S; Chung A; Martin T; Wolf J; Wong SW; Shah N; Banerjee R
Leuk Lymphoma; 2023 Jun; 64(6):1186-1193. PubMed ID: 37096638
[TBL] [Abstract][Full Text] [Related]
4. Application of urine immunofixation electrophoresis in prognostic evaluation of hematopoietic stem cell transplantation in patients with myeloma.
Zhu S; Yang C; Li W; Lin M
Pak J Med Sci; 2022; 38(1):315-319. PubMed ID: 35035446
[TBL] [Abstract][Full Text] [Related]
5. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
7. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Singh G; Bollag R
Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
[TBL] [Abstract][Full Text] [Related]
8. Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.
Tosi P; Tomassetti S; Merli A; Polli V
Ther Adv Hematol; 2013 Feb; 4(1):37-41. PubMed ID: 23610612
[TBL] [Abstract][Full Text] [Related]
9. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
Singh G
J Appl Lab Med; 2020 Nov; 5(6):1358-1371. PubMed ID: 33150391
[TBL] [Abstract][Full Text] [Related]
10. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
11. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
12. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
13. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
14. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
15. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
16. Differences identified between serum and urine immunofixation electrophoresis.
Tracy E; Andrews DM; Constantin MA; Zhu Y
Clin Chim Acta; 2015 Jan; 439():68-70. PubMed ID: 25307209
[TBL] [Abstract][Full Text] [Related]
17. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.
Abbi KK; Silverman M; Farooq U; Tricot A; Dozeman L; Nadiminti K; Krasowski MD; Tricot GJ
Br J Haematol; 2016 Aug; 174(4):536-40. PubMed ID: 27172326
[TBL] [Abstract][Full Text] [Related]
18. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P; Rocchi S; Zamagni E; Barbato S; Rizzello I; De Cicco G; Pantani L; Mancuso K; Fusco A; Dozza L; Ursi M; Favero E; Terragna C; Testoni N; Cavo M
Am J Hematol; 2022 Dec; 97(12):1607-1615. PubMed ID: 36198076
[TBL] [Abstract][Full Text] [Related]
19. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies.
Harding SJ; Mead GP; Bradwell AR; Berard AM
Clin Chem Lab Med; 2009; 47(3):302-4. PubMed ID: 19676141
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
